Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.53 USD | +0.31% | -2.96% | -6.71% |
05-17 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.71% | 18.34M | |
+39.66% | 723B | |
+34.28% | 595B | |
-3.66% | 369B | |
+20.23% | 332B | |
+2.84% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.10% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc., Q4 2019 Earnings Call, Feb 12, 2020